Published: May 13, 2021
BERKELEY HEIGHTS, N.J., May 13, 2021 (GLOBE NEWSWIRE) CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced the appointment of Thomas Nusbickel to the newly created position of Chief Commercial Officer. Tom will be responsible for advancing the commercial strategy needed to bring DefenCath to patients in the US when approved by FDA for commercial distribution.
Khoso Baluch, Chief Executive Officer of CorMedix, commented, “Tom represents a key addition to our executive team as he brings decades of leadership experience in commercial strategy and highly relevant experience in the renal disease space. As we are eager to continue planning in preparation for our commercial launch of DefenCath, Tom will be well positioned to lead and strengthen the commercial effort for CorMedix.”